UCB stock: Guidance rests on BIMZELX and CIMZIA demand
Published on 11/03/2026 at 17:52 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSGrowth drivers and investor focus
- BIMZELX demand in the United States and CIMZIA volume growth underpin the revised outlook.
- UCB's portfolio includes more than 135,000 BIMZELX patients globally and sales of EUR 1.52 billion in the first half of 2026.
- Full-year results and formal 2027 guidance are scheduled for February 25, 2027.
UCB's October 22 guidance upgrade remains the central issue for investors after the company pointed to stronger BIMZELX demand and continued CIMZIA volume growth. UCB's investor materials support the commercial backdrop, highlighting more than 135,000 BIMZELX patients globally in the first half of 2026 and sales of EUR 1.52 billion.
UCB stock traded at 276.10 euros on Lang & Schwarz at 17:46 CET on Tuesday, November 3, 2026. The quote was 1.92 percent below the 281.50-euro Lang & Schwarz quote cited in the previous report published on October 30, a separate comparison from the daily exchange-session move.
The real-time quote of UCB stock gives investors a live view of the Brussels-listed company.
What has changed since our last report
The latest guidance calls for 2026 revenue growth in the low twenties at constant exchange rates, compared with the previous low-to-mid-teens range. Adjusted EBITDA growth is expected in the low-to-mid-forties, up from the prior mid-teens to low-twenties range.
UCB attributes the stronger outlook mainly to BIMZELX performance in the United States, including patient conversion, retention and net pricing. CIMZIA continues to add volume across markets despite a contracting anti-TNF market. The revised targets exclude proceeds from a potential Priority Review Voucher sale, which UCB said could provide an additional low-to-mid-single-digit percentage-point uplift to revenue and adjusted EBITDA growth.
The portfolio remains broader than the two main immunology drivers. UCB's investor page lists EUR 954 million in CIMZIA sales, EUR 239 million in FINTEPLA sales and EUR 192 million in RYSTIGGO sales for the first half of 2026. The company also reports EUR 139 million in ZILBRYSQ sales and EUR 327 million in BRIVIACT sales for the period.
UCB's next scheduled catalyst is the publication of full-year 2026 results and formal 2027 guidance on February 25, 2027. That update should show whether the stronger commercial performance translated into the expected operating leverage.
The broader European market backdrop can be followed through current Euro Stoxx 50 market reports.
For more company-specific developments, see more news and analyses on UCB stock.
UCB company and quote
- Company: UCB S.A.
- ISIN: BE0003739530
- Listing: Euronext Brussels
- Quote: 276.10 euros at 17:46 CET on November 3, 2026 at Lang & Schwarz
- Change since October 30 report: 1.92 percent lower than 281.50 euros
